La chaîne d'options affiche les données clés des options sur actions de Armata Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Armata Pharmaceuticals..

Armata Pharmaceuticals (AMEX:ARMP) Stock, Chaîne d'Options

ARMATA PHARMACEUTICALS INC

Armata Pharmaceuticals

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals Inc

Press Releases

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Earnings

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

This $13M Biotech Has $40M in Pentagon Funding – Here's Why BiomX Could Be Biotech's Best-Kept Secret

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Personal Finance

Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill Bacteria?

ARMP

PHGE

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Elicio Therapeutics

Fate Therapeutics

Forte Biosciences

Genfit

Heron Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Nkarta

Nuvectis Pharma

Palisade Bio

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Comments

Armata Pharmaceuticals

Armata Pharmaceuticals (ARMP) Options

Armata Pharmaceuticals (AMEX:ARMP) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL